全球基因组编辑市场规模、份额、趋势和成长分析报告（2026-2034）

基因组编辑市场预计将从 2025 年的 88.1 亿美元成长到 2034 年的 289.6 亿美元，2026 年至 2034 年的复合年增长率为 14.14%。

受基因工程技术进步的推动，全球基因组编辑市场正经历显着成长。诸如基于CRISPR的系统等工具能够对DNA序列进行精确修改，用于研究和治疗目的。人们对基因治疗、农业生物技术和疾病建模日益增长的兴趣也促进了市场扩张。生物技术研究投入的增加正在加速进一步的创新。

主要成长要素包括对个人化医疗和遗传疾病治疗日益增长的需求。製药公司正在推进基因组编辑技术在标靶治疗的研究。已开发地区政府的资金投入和法规环境的改善正在加强相关研究活动。此外，作物改良和畜牧育种等领域的广泛应用也促进了市场成长。

技术进步提高了基因编辑的精确度和安全性，从而为未来发展奠定了坚实的基础。新兴市场对生物技术基础设施的投资将创造新的机会。伦理考虑和监管趋势预计将影响市场动态。随着基因研究的不断发展，全球基因组编辑市场预计将持续成长。

目录

第一章：引言

第二章执行摘要

第三章 市场变数、趋势与框架

• 市场谱系展望
• 渗透率和成长前景分析
• 价值链分析
• 法律规范
  • 标准与合规性
  • 监管影响分析
• 市场动态
  • 市场驱动因素
  • 市场限制因素
  • 市场机会
  • 市场挑战
• 波特五力分析
• PESTLE分析

第四章：全球基因组编辑市场：依技术划分

• 市场分析、洞察与预测
• CRISPR/Cas9
• TALENs/MegaTALs
• 主编
• 低音编辑
• Cpf1（源自普雷沃氏菌属和弗朗西斯氏菌属的 CRISPR 1）
• CasX 和 CasY
• ZFN
• Meganucleases
• 寡核苷酸诱导突变（ODM）
• 合成基因编辑工具
• 转录活化因子样效应器低音编辑器 (TALE-BE)
• 其他的

第五章 全球基因组编辑市场：依交付方式划分

• 市场分析、洞察与预测
• Ek Vivo
• 体内

第六章 全球基因组编辑市场：依应用领域划分

• 市场分析、洞察与预测
• 基因工程（细胞株工程、动物基因工程、植物基因工程等）
• 临床应用（诊断、治疗研发）
• 其他的

第七章 全球基因组编辑市场：依最终用途划分

• 市场分析、洞察与预测
• 生物技术和製药公司
• 学术研究机构与政府研究机构
• 受託研究机构

第八章：全球基因组编辑市场：依模式划分

• 市场分析、洞察与预测
• 合约
• 内部开发

第九章 全球基因组编辑市场：依地区划分

• 区域分析
• 北美市场分析、洞察与预测
  • 我们
  • 加拿大
  • 墨西哥
• 欧洲市场分析、洞察与预测
  • 英国
  • 法国
  • 德国
  • 义大利
  • 俄罗斯
  • 其他欧洲国家
• 亚太市场分析、洞察与预测
  • 印度
  • 日本
  • 韩国
  • 澳洲
  • 东南亚
  • 其他亚太国家
• 拉丁美洲市场分析、洞察与预测
  • 巴西
  • 阿根廷
  • 秘鲁
  • 智利
  • 其他拉丁美洲国家
• 中东和非洲市场分析、洞察与预测
  • 沙乌地阿拉伯
  • UAE
  • 以色列
  • 南非
  • 其他中东和非洲国家

第十章 竞争格局

• 最新趋势
• 公司分类
• 供应链和销售管道合作伙伴（根据现有资讯）
• 市场占有率和市场定位分析（基于现有资讯）
• 供应商情况（基于现有资讯）
• 策略规划

第十一章：公司简介

• 主要公司的市占率分析
• 公司简介
  • Merck KGaA
  • Cibus Inc
  • Recombinetics
  • Sangamo Therapeutics
  • Editas Medicine
  • Precision Biosciences
  • CRISPR Therapeutics
  • Intellia Therapeutics Inc
  • Caribou Biosciences Inc
  • Cellectis SA
  • AstraZeneca
  • Takara Bio Inc
  • Horizon Discovery Ltd.（Revvity Inn Inc.）

The Genome Editing Market size is expected to reach USD 28.96 Billion in 2034 from USD 8.81 Billion (2025) growing at a CAGR of 14.14% during 2026-2034.

The Global Genome Editing Market is witnessing significant growth driven by advancements in genetic engineering technologies. Tools such as CRISPR-based systems are enabling precise modification of DNA sequences for research and therapeutic purposes. Increasing focus on gene therapy, agricultural biotechnology, and disease modeling is supporting market expansion. Rising investments in biotechnology research are further accelerating innovation.

Major growth drivers include growing demand for personalized medicine and treatment of genetic disorders. Pharmaceutical companies are exploring genome editing for targeted therapies. Government funding and supportive regulatory frameworks in developed regions are strengthening research activities. Additionally, expanding applications in crop improvement and livestock breeding are contributing to market growth.

Future prospects remain strong as technological advancements improve editing accuracy and safety. Emerging markets investing in biotechnology infrastructure will present new opportunities. Ethical considerations and regulatory developments will shape market dynamics. As genetic research continues to evolve, the Global Genome Editing Market is projected to experience sustained expansion.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Technology

• CRISPR/Cas9
• TALENs/MegaTALs
• Prime Editing
• Base Editing
• Cpf1 (CRISPR from Prevotella and Francisella 1)
• CasX and CasY
• ZFN
• Meganucleases
• Oligonucleotide-Directed Mutagenesis (ODM)
• Synthetic Gene Editors
• Transcription Activator-Like Effector Base Editors (TALE-BE)
• Other

By Delivery Method

• Ex-vivo
• In-vivo

By Application

• Genetic Engineering (Cell Line Engineering, Animal Genetic Engineering, Plant Genetic Engineering, Others)
• Clinical Applications (Diagnostics, Therapy Development)
• Others

By End-use

• Biotechnology and Pharmaceutical Companies
• Academic and Government Research Institutes
• Contract Research Organizations

By Mode

• Contract
• In-House

COMPANIES PROFILED

• Merck KGaA, Cibus Inc, Recombinetics, Sangamo Therapeutics, Editas Medicine, Precision Biosciences, CRISPR Therapeutics, Intellia Therapeutics Inc, Caribou Biosciences Inc, Cellectis SA, AstraZeneca, Takara Bio Inc, Horizon Discovery Ltd Revvity Inn Inc
• We can customise the report as per your requirements.

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL GENOME EDITING MARKET: BY TECHNOLOGY 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Technology
• 4.2. CRISPR/Cas9 Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. TALENs/MegaTALs Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.4. Prime Editing Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.5. Base Editing Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.6. Cpf1 (CRISPR from Prevotella and Francisella 1) Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.7. CasX and CasY Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.8. ZFN Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.9. Meganucleases Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.10. Oligonucleotide-Directed Mutagenesis (ODM) Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.11. Synthetic Gene Editors Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.12. Transcription Activator-Like Effector Base Editors (TALE-BE) Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.13. Other Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL GENOME EDITING MARKET: BY DELIVERY METHOD 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Delivery Method
• 5.2. Ex-vivo Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. In-vivo Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL GENOME EDITING MARKET: BY APPLICATION 2022-2034 (USD MN)

• 6.1. Market Analysis, Insights and Forecast Application
• 6.2. Genetic Engineering (Cell Line Engineering, Animal Genetic Engineering, Plant Genetic Engineering, Others) Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.3. Clinical Applications (Diagnostics, Therapy Development) Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.4. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL GENOME EDITING MARKET: BY END-USE 2022-2034 (USD MN)

• 7.1. Market Analysis, Insights and Forecast End-use
• 7.2. Biotechnology and Pharmaceutical Companies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.3. Academic and Government Research Institutes Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.4. Contract Research Organizations Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 8. GLOBAL GENOME EDITING MARKET: BY MODE 2022-2034 (USD MN)

• 8.1. Market Analysis, Insights and Forecast Mode
• 8.2. Contract Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 8.3. In-House Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 9. GLOBAL GENOME EDITING MARKET: BY REGION 2022-2034(USD MN)

• 9.1. Regional Outlook
• 9.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 9.2.1 By Technology
  • 9.2.2 By Delivery Method
  • 9.2.3 By Application
  • 9.2.4 By End-use
  • 9.2.5 By Mode
  • 9.2.6 United States
  • 9.2.7 Canada
  • 9.2.8 Mexico
• 9.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 9.3.1 By Technology
  • 9.3.2 By Delivery Method
  • 9.3.3 By Application
  • 9.3.4 By End-use
  • 9.3.5 By Mode
  • 9.3.6 United Kingdom
  • 9.3.7 France
  • 9.3.8 Germany
  • 9.3.9 Italy
  • 9.3.10 Russia
  • 9.3.11 Rest Of Europe
• 9.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 9.4.1 By Technology
  • 9.4.2 By Delivery Method
  • 9.4.3 By Application
  • 9.4.4 By End-use
  • 9.4.5 By Mode
  • 9.4.6 India
  • 9.4.7 Japan
  • 9.4.8 South Korea
  • 9.4.9 Australia
  • 9.4.10 South East Asia
  • 9.4.11 Rest Of Asia Pacific
• 9.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 9.5.1 By Technology
  • 9.5.2 By Delivery Method
  • 9.5.3 By Application
  • 9.5.4 By End-use
  • 9.5.5 By Mode
  • 9.5.6 Brazil
  • 9.5.7 Argentina
  • 9.5.8 Peru
  • 9.5.9 Chile
  • 9.5.10 South East Asia
  • 9.5.11 Rest of Latin America
• 9.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 9.6.1 By Technology
  • 9.6.2 By Delivery Method
  • 9.6.3 By Application
  • 9.6.4 By End-use
  • 9.6.5 By Mode
  • 9.6.6 Saudi Arabia
  • 9.6.7 UAE
  • 9.6.8 Israel
  • 9.6.9 South Africa
  • 9.6.10 Rest of the Middle East And Africa

Chapter 10. COMPETITIVE LANDSCAPE

• 10.1. Recent Developments
• 10.2. Company Categorization
• 10.3. Supply Chain & Channel Partners (based on availability)
• 10.4. Market Share & Positioning Analysis (based on availability)
• 10.5. Vendor Landscape (based on availability)
• 10.6. Strategy Mapping

Chapter 11. COMPANY PROFILES OF GLOBAL GENOME EDITING INDUSTRY

• 11.1. Top Companies Market Share Analysis
• 11.2. Company Profiles
  • 11.2.1 Merck KGaA
  • 11.2.2 Cibus Inc
  • 11.2.3 Recombinetics
  • 11.2.4 Sangamo Therapeutics
  • 11.2.5 Editas Medicine
  • 11.2.6 Precision Biosciences
  • 11.2.7 CRISPR Therapeutics
  • 11.2.8 Intellia Therapeutics Inc
  • 11.2.9 Caribou Biosciences Inc
  • 11.2.10 Cellectis S.A
  • 11.2.11 AstraZeneca
  • 11.2.12 Takara Bio Inc
  • 11.2.13 Horizon Discovery Ltd. (Revvity Inn Inc.)